



20 April 2020

Sydney, Australia

Receipt of cash payment for collateral shares

Highlights

- Receipt of \$409,477 cash in relation to 3.69 million collateral shares
 - Outstanding 0.81 million collateral share liability payable to Noxopharm by 20 Dec 2021
-

Sydney, 20 April 2020: Noxopharm (ASX: NOX) wishes to advise that it has received cash payments of \$409,477 in relation to a portion of the collateral shares that Noxopharm previously issued under the historical convertible security agreements with Lind Partners, LLC and CST Investment Funds (the **Lenders**). These agreements were recently terminated, as announced by the company on 14th February 2020.

Noxopharm previously issued 4.50 million ordinary shares in aggregate to the Lenders as collateral shares under the convertible security agreements (2.25 million shares per Lender).

The Lenders are required, by 20th December 2021, to pay to Noxopharm in cash the collateralisation price for the outstanding collateral shares. The collateralisation price per collateral share is the lower of:

- 90% of the average of the 5 lowest daily VWAPs of NOX shares during the 20 trading day period prior to the date immediately prior to the payment date; and
- \$0.477.

Noxopharm has received total cash payments of \$409,477 in relation to 3,688,978 collateral shares as detailed below:

- \$159,727 from CST Investment Funds in relation to 1,438,978 collateral shares, at a collateralisation price of 11.1 cents per collateral share, reducing the CST Investment Funds outstanding collateral share liability from 2.25 million collateral shares to 811,022; and
- \$249,750 from Lind Partners, LLC in relation to 2,250,000 collateral shares reducing the Lind Partners, LLC outstanding collateral share liability from 2.25 million collateral shares to zero.



CST Investment Funds is contractually required to pay the remaining cash value of the outstanding 811,022 collateral shares, calculated according to the pricing structure outlined above, to Noxopharm by 20th December 2021.

About Noxopharm

Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda[®] and is the major shareholder in the non-oncology drug development company, Nyrada Inc. (ASX:NYR).

www.noxopharm.com

Investor & Corporate Enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media queries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

Graham Kelly, CEO and Chairman of Noxopharm, has approved the release of this document to the market.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.